Isocitrate dehydrogenase mutations in gliomas
Current Opinion in Neurology2011Vol. 24(6), pp. 648–652
Citations Over TimeTop 11% of 2011 papers
Abstract
As valuable diagnostic and prognostic markers of human gliomas, there is still a lack of knowledge on biological functions of mutant IDHs, making targeting IDHs in glioma both difficult and unsecured.
Related Papers
- → IDH1andIDH2Mutations in Gliomas(2009)5,883 cited
- → Isocitrate dehydrogenase-1 mutations: a fundamentally new understanding of diffuse glioma?(2010)216 cited
- → Isocitrate dehydrogenase mutations in gliomas(2011)86 cited
- → Implications of Concurrent IDH1 and IDH2 Mutations on Survival in Glioma—A Case Report and Systematic Review(2022)12 cited
- → Molecular Investigation of Isocitrate Dehydrogenase Gene (IDH) Mutations in Gliomas: First Report of IDH2 Mutations in Indian Patients(2013)18 cited